tirzepatide kidney improves outcomes in T2DM with increased CV risk Tirzepatide and Chronic Kidney Disease:

Oral semaglutide 14 mg was therefore associated with ICERs of EUR 29,920 per QALY gained versus empagliflozin 25 mg and EUR 15,258 per QALY gained versus dulaglutide 1.5 mg in the probabilistic analysis

Oral semaglutide, Indian Prescribing information Last accessed on 2021 Dec 29 32

Start with 3 to 4 times daily for one to two weeks, then taper based on symptoms

Design: Thirty-six week, open-label lead-in treatment with tirzepatide, followed by 52-week, randomized, double-blind, placebo-controlled withdrawal trial

As an additional safety measure, all patients in Europe had additional laboratory data collection at weeks 4, 8, 12 and 16, with creatinine and UACR tests performed at the central laboratory, and the CKD-EPI 2021 equation used for eGFR